Floatz logo

Ezabenlimab

Pancreatic Neoplasm

Boehringer Ingelheimmonoclonal_antibodyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
59/ 100

Competitive context

381 Active assets in the Pancreatic Neoplasm cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Ezabenlimab is also rated in:

metastatic malignant neoplasmDormant
B
Indicative ·
63 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →
neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →